Browsing Tag
Hyloris Pharmaceuticals
3 posts
Is AFT Pharmaceuticals undervalued after NZ$208m in FY25 Revenue? What’s next for AFP stock
AFT Pharmaceuticals posts NZ$208M record revenue in FY25. Find out why investors are eyeing its NZ$300M growth target despite short-term profit dips.
RedHill Biopharma secures $60m licensing agreement with Hyloris for global commercialization of RHB-102
RedHill Biopharma Ltd. has entered into an exclusive licensing agreement with Hyloris Pharmaceuticals SA, granting the Belgian company…
Hyloris Pharmaceuticals buys global rights to CRD-102 from Baker Institute
Hyloris Pharmaceuticals has acquired the global rights from Australia-based Baker Heart and Diabetes Institute (Baker Institute) to CRD-102,…